Type 2 Diabetics have a reason to optimistic as a new medical breakthrough could lead to a big change in their lifestyle. Toronto researcher Dr Daniel Drucker, who is a world expert in the development of peptide hormone based therapies for the treatment of human disease, has accomplished a biomedical research that enables Diabetic patient to undergo twice-weekly injection instead of the more common twice daily injection. The new treatment called Exenatide reportedly provides a long-lasting effect on the patient and also poses fewer side-effects. The release of this treatment (by early 2009) would be particularly useful for the 2 million diabetic patients in Canada as there is no available therapy for type 2 diabetic patients that they can receive once a week.

Source